Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy

References

• Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer 1 Gun. 54,8-29 (2004).
   Google Scholar
• Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 64, 529–564 (1994).
   PubMed Web of Science ®Google Scholar
• Sparwasser T, Vabulas RM, Villmow B, Lipford GB, Wagner H. Bacterial CpG-DNA activates dendritic cells in vivo: T-helper cell-independent cytotoxic T-cell responses to soluble proteins. Eur. Immunol 30,3591–3597 (2000).
   Google Scholar
• •Important study describing the activation of dendritic cells by bacterial CpG-DNA via T-helper cell-independent mechanisms.
   Google Scholar
• Carpenter AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. 59,5429–5432 (1999).
   PubMed Web of Science ®Google Scholar
• •Describes the ability of CpG oligodeoxynucleotides to induce antitumor activity in viva
   Google Scholar
• Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228,307-319 (1998).
   Google Scholar
• •Describes factors associated with responses to interleukin
   Google Scholar
• Espinoza-Delgado I. Cancer vaccines. Oncologist 7\(Suppl. 3), 20–33 (2002).
   Google Scholar
• Fenton RG, Longo DL. Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T-lymphocytes. Natl Cancer Inst. 89,272–275 (1997).
   Google Scholar
• Whiteside TL. Signaling defects in T-lympho- cytes of patients with malignancy. Cancer humunol. Immunother 48,346–352 (1999).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR et al Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Merl 2, 1096–1103 (1996).
   PubMed Web of Science ®Google Scholar
• ••Landmark study identifying vascularendothelial growth factor receptor (VEGF) as an inhibitor of dendritic cell activation and differentiation in tumor-bearing hosts.
   Google Scholar
• Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 157,125–140 (1997).
   PubMed Web of Science ®Google Scholar
• •Excellent review discussing the major role of minor histocompatibility antigens in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) in hemato-poietic stem cell transplantation (HSCT).
   Google Scholar
• Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. B/ooc/91, 2197–2207 (1998).
   Google Scholar
• Kolb HJ, Mittermuller J, Clemm C et al Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462–2465 (1990).
   PubMed Web of Science ®Google Scholar
• ••Pioneer work demonstrating the potentgraft-versus-leukemia effect of donor lymphocyte infusions.
   Google Scholar
• Ueno NT, Rondon G, Mirza NQ et al Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. j Clin. Oiled 16, 986–993 (1998).
   PubMed Web of Science ®Google Scholar
• •Pioneer study demonstrating regression of liver metastasis in association with the development of skin GVHD in the setting of myeloablative HSCT.
   Google Scholar
• Buckner CD, Clift RA, Fefer A et al. Marrow transplantation for the treatment of acute leukemia using HLA-identical siblings. 7iamplant. Floc 6,365–366 (1974).
   Google Scholar
• Maraninchi D, Gluckman E, Blaise D et al. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard-risk leukemias. Lancet2,175–178 (1987).
   PubMed Web of Science ®Google Scholar
• Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft versus host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl. Merl 304,1529–1533 (1981).
   Google Scholar
• •Landmark study demonstrating an association between GVHD and antileukemic effect.
   Google Scholar
• Horowitz MM, Gale RP, Sondel PM et al Graft-versus-leukemia reactions after bone marrow transplantation. Blooc175, 555–562 (1990).
   Google Scholar
• Sullivan KM, Storb R, Buckner CD et al. Graft versus host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl. I Med. 320,828–834 (1989).
   PubMed Web of Science ®Google Scholar
• Fefer A, Cheever MA, Greenberg PD. Identical-twin (syngeneic) marrow transplantation for hematologic cancers. Natl Cancer Inst. 76,1269–1273 (1986).
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM et al Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. B/ooc/86,2041–2050 (1995).
   Google Scholar
• Drobyski WR, Keever CA, Roth MS et al Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. B/ooc/82,2310–2318 (1993).
   Google Scholar
• Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LE Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90, 4206–4211 (1997).
   PubMed Web of Science ®Google Scholar
• Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. B/ooc/90,4201–4205 (1997).
   Google Scholar
• Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus- malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Clin. arca 16,2817–2824 (1998).
   Google Scholar
• Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet347, 800–801 (1996).
   Google Scholar
• Rondon G, Giralt S, Huh Y et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18,669–672 (1996).
   PubMed Web of Science ®Google Scholar
• Childs R, Chernoff A, Contentin N et al Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl. I Merl 343,750-758 (2000). Landmark study providing first evidence of graft-versus-solid tumor effect in the setting of nonrnyeloablative HSCT. Responses occurred most frequently in patients with slow-growing tumors and full-donor T-cell chimerism.
   Google Scholar
• Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer80, 1273–1283 (1997).
   PubMed Web of Science ®Google Scholar
• Visseren MJ, van der Burg SH, Hawes GE, van der Voort EL van den Elsen PJ, Melief CJ. Affinity, specificity and T-cell-receptor diversity of melanoma-specific CTL generated in vitro against a single tyrosinase epitope. mt. J. Cancer 72, 1122–1128 (1997).
   Google Scholar
• Morse MA, Deng Y, Coleman D et al A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 5,1331-1338 (1999).
   Google Scholar
• Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29,371–380 (1996).
   Google Scholar
• Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61,842–847 (2001).
   PubMed Web of Science ®Google Scholar
• Disis ML, Schiffman K. Issues on clinical applications of cancer vaccines. Immunother. 24,104–105 (2001).
   Web of Science ®Google Scholar
• Moscovitch M, Slavin S. Antitumor effects of allogeneic bone marrow transplantation in (NZB X NZVV)F1 hybrids with spontaneous lymphosarcoma. j Immunol 132,997–1000 (1984).
   PubMed Web of Science ®Google Scholar
• •First study demonstrating allogeneic graft-versus-solid tumor response in a preclinical model.
   Google Scholar
• Morecki S, Moshel Y, Gelfend Y, Pugatsch T, Slavin S. Induction of graft-versus-tumor effect in a murine model of mammary adenocarcinoma. Int. I Cancer 71,59–63 (1997).
   Google Scholar
• Morecki S, Yacovlev E, Diab A, Slavin S. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res. 58, 3891–3895 (1998).
   PubMed Web of Science ®Google Scholar
• Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 348,1242–1243 (1996).
   Google Scholar
• ••Earliest evidence of graft-versus-solidtumor effect in humans.
   Google Scholar
• Eibl B, Schwaighofer H, Nachbaur D et al Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blooc188, 1501–1508 (1996).
   Google Scholar
• ••Earliest evidence of graft-versus-solidtumor effect in humans.
   Google Scholar
• Ueno NT, Rizzo JD, Hegenbart U et al International Bone Marrow Transplant Registry/The European Group for Blood and Marrow Transplantation (IBMTR/EBMT) review of allogeneic hematopoietic stem-cell transplantation (ALLO HSCT) in metastatic breast cancer (MBC). Proc. Am Soc. Clin. Oncol (2003) (Abstract 3345).
   Google Scholar
• Moscardo F, Martinez JA, Sanz GF et al Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. BE 1-Lematol. 111,708-710 (2000).
   Google Scholar
• Bay JO, Fleury J, Choufi B et al Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant. 30,95–102 (2002).
   PubMed Web of Science ®Google Scholar
• •Provides evidence of some GVT effect against ovarian carcinoma in a nonrnyeloablative setting.
   Google Scholar
• Motzer RJ, Rakhit A, Schwartz LH et al Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. 4,1183-1191 (1998).
   Google Scholar
• Finke JH, Rayman P, Edinger M et al Characterization of a human renal cell carcinoma specific cytotoxic CD8* T-cell line. Immunother. 11,1–11 (1992).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 411,380–384 (2001).
   PubMed Web of Science ®Google Scholar
• Childs R, Clave E, Contentin N et al Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. B/ooc/94,3234–3241 (1999).
   Google Scholar
• Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. j Clin. Oncol 17,2044–2049 (1999).
   PubMed Web of Science ®Google Scholar
• •Emphasizes the relevance of lineage-specific chimerism analysis to successfully manipulate engraftment after nonmyeloablative HSCT.
   Google Scholar
• Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J. Clin. Oncol 20, 2017-2024 (2002).
   Google Scholar
• Pedrazzoli P, Da Prada GA, Giorgian G et al Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer94, 2409–2415 (2002).
   PubMed Web of Science ®Google Scholar
• •Emphasizes the importance of patient selection for a successful outcome. Patients with poor performance status are not good candidates for nonmyeloablative HSCT.
   Google Scholar
• Bregni M, Dodero A, Peccatori J et al Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. B/ooc/99,4234–4236 (2002).
   Google Scholar
• Hentschke P, Barkholt L, Uzunel M et al Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone MarIVW 7iamplant. 31,253-261 (2003).
   Google Scholar
• Blaise D, Bay JO, Faucher C et al Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood103, 435–441 (2004).
   PubMed Web of Science ®Google Scholar
• Ueno NT, Cheng YC, Rondon G et al Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. B/ooc/102,3829–3836 (2003).
   Google Scholar
• •Evidence of GVT against breast cancer in the setting of nonmyeloablative HSCT. Confirmation of GVT against renal cell carcinoma is also provided.
   Google Scholar
• Peccatori J, Bregni M. Allogeneic non-myeloablative peripheral-blood stem cell transplant in solid tumors. Suppl Tumor] 1, S32—S33 (2002).
   Google Scholar
• Childs R, Gotlieb D. Non-myeloablative allogeneic stem cell transplantation for metastatic melanoma: nondurable chemotheraphy responses without clinically meaningful graft-vs-tumor effects.Blood (2002) (Abstract 1661))
   Google Scholar
• Makimoto A, Kami M, Mineishi S et al Reduced-intensity allogeneic stem-cell transplantation for patients including children with refractory sarcoma.
   Google Scholar
• Castagna L, Bertuzzi A, Nozza A et al Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas. Bone Marrow Transplant. 30,207–214 (2002).
   PubMed Web of Science ®Google Scholar
• Zetterquist H, Hentschke P, Thorne A et al. A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplant 28,1161–1166 (2001).
   PubMedGoogle Scholar
• Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer 1 10, 1–7 (2004).
   Google Scholar
• •Excellent review describing the potential of minor antigens as potential targets for immunotherapy.
   Google Scholar
• Grosse-Wilde H, Krumbacher K,Schunning F et al. Immune transfer studies in canine allogenic marrow graft donor recipient pairs.Transplation 42, 64–67(1986).
   Google Scholar
• Lum LG, Munn NA, Schanfield MS, Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345,1016–1020 (1995).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotipye specific immunity from an actively immunised marrow donor. Lancent 345,1016–1020(1995).
   PubMed Web of Science ®Google Scholar
• •Pioneering study describing the transfer of specific tumor antigen immunity from an immunized donor to the recipient.
   Google Scholar
• Ruggeri L, Capanni M, Casucci M et al Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94,333–339 (1999).
   PubMed Web of Science ®Google Scholar
• •Pioneering study describing the ability of donor natural killer (N1c) cells to exert alloirnmune cytotoxicity in the setting of KIR mismatch between donor and recipient.
   Google Scholar
• Ruggeri L, Capanni M, Urbani E et al Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295,2097–2100 (2002).
   PubMed Web of Science ®Google Scholar
• Igarashi T, Wynberg J, Srinivasan R et al Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. B/ooc/104,170-177 (2004). Enhanced cytotoxicity of K1R-incompatible NK cells against solid tumors.
   Google Scholar
• Espinoza-Delgado IJ, Shetty V, Geller N et al Impact of age on transplant related mortality following fludarabine and cyclophosphamide-based nonmyeloablative allogeneic hematopoietic cell transplantation. Blood (2003) (Abstract 2656).
   Google Scholar
• Louria DB, Sen P, Sherer CB, Farrer WE. Infections in older patients: a systematic clinical approach. Geriatrics 48,28–34 (1993).
   PubMed Web of Science ®Google Scholar
• Castle SC. Clinical relevance of age-related immune dysfunction. din. Infect. Dis. 31, 578–585 (2000).
   PubMed Web of Science ®Google Scholar
• Antonini JM, Roberts JR, Clarke RW et al Effect of age on respiratory defense mechanisms: pulmonary bacterial clearance in Fischer 344 rats after intratracheal instillation of Listeria monocytogenes. Chest 120,240-249 (2001). Ordemann R, Hutchinson R, Friedman J et al Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft versus host disease. Clin. Invest. 109,1249-1256 (2002). Describes that the increased incidence of GVHD observed in eldely recipients is related to the enhanced allostimulatory activity of host antigen-presenting cells.
   Google Scholar
• Shlomchik WD, Couzens MS, Tang CB et al Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science 285,412–415 (1999).
   PubMed Web of Science ®Google Scholar
• Landmark manuscript demonstrating the critical role of host antigen-presenting cells in the development of GVHD in a murine model.
   Google Scholar
• Thomas E, Storb R, Clift RA et al. Bone-marrow transplantation (first of two parts). NEngif Med. 292,832–843 (1975).
   PubMed Web of Science ®Google Scholar
• Couriel DR, Saliba RM, Giralt S et al Acute and chronic graft versus host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol. Blood Marrow Transplant 10, 178–185 (2004).
   PubMed Web of Science ®Google Scholar
• •Single-institution study evaluating the effects of the conditioning regimen in the incidence of GVHD. Patients received same GVHD prophylaxes. Provides evidence that a nonmyeloablative conditioning regimen is associated with less GVHD.
   Google Scholar
• Amrolia PJ, Reid SD, Gao L et al Allorestricted cytotoxic T-cells specific for human CD45 show potent antileukemic activity. Blood 101, 1007–1014 (2003).
   PubMed Web of Science ®Google Scholar
• Solomon SR, Tran T, Carter CS et al Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 4, 395–406 (2004).
   Web of Science ®Google Scholar
• Guinan EC, Boussiotis VA, Neuberg D et al Transplantation of anergic histoincompatible bone marrow allografts. N. Engl Med 340,1704–1714 (1999).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Molina AJ, Sahebi F et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood102,3447–3454 (2003).
   PubMed Web of Science ®Google Scholar
• Carella AM, Beltrami G, Lerma E, Cavaliere M, Corsetti MT Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer. Cancer Treat. Res. 110, 101–112 (2002).
   PubMedGoogle Scholar
• Tykodi SS, Warren EH, Thompson JA et al Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nommyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. (2004) (In Press).
   Google Scholar